Avidity Biosciences, Inc. (RNA) Equity Ratio (2019 - 2025)
Avidity Biosciences' Equity Ratio history spans 7 years, with the latest figure at 0.86 for Q4 2025.
- For Q4 2025, Equity Ratio fell 5.35% year-over-year to 0.86; the TTM value through Dec 2025 reached 0.86, down 5.35%, while the annual FY2025 figure was 0.86, 5.35% down from the prior year.
- Equity Ratio reached 0.86 in Q4 2025 per RNA's latest filing, down from 0.88 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.93 in Q3 2021 to a low of 0.8 in Q4 2023.
- Average Equity Ratio over 5 years is 0.89, with a median of 0.9 recorded in 2022.
- Peak YoY movement for Equity Ratio: dropped 11.96% in 2023, then grew 14.37% in 2024.
- A 5-year view of Equity Ratio shows it stood at 0.89 in 2021, then rose by 1.44% to 0.9 in 2022, then dropped by 11.96% to 0.8 in 2023, then rose by 14.37% to 0.91 in 2024, then dropped by 5.35% to 0.86 in 2025.
- Per Business Quant, the three most recent readings for RNA's Equity Ratio are 0.86 (Q4 2025), 0.88 (Q3 2025), and 0.87 (Q2 2025).